Rhythm Pharmaceuticals
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Massachusetts, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
222 Berkeley St Fl 12, Boston, Massachus...Phone Number
(857) 264-4280Website
www.rhythmtx.comRevenue
$217.2 MillionStock Symbol
RYTMIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Rhythm Pharmaceuticals
Rhythm Pharmaceuticals is a biopharmaceutical research and development company focused on developing precision medicines for rare genetic obesity disorders. The company specializes in treatments targeting the melanocortin-4 receptor pathway diseases that cause hyperphagia and severe obesity. Founded in 2008, Rhythm Pharmaceuticals conducts scientific research to address the root causes of these rare conditions, advancing therapeutic solutions for patients with these specific genetic disorders. The company operates internationally with presence in North America and Europe, including France and the Netherlands.Explore more
Rhythm Pharmaceuticals Org Chart
Get the full picture
Sign in to uncover key details.
TS
Senior Director, Human Resources & Business P...
HT
Director, Human Resources, International (Jap...
TM
Director, Field Development
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Rhythm Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Rhythm Pharmaceuticals
Click to see if Rhythm Pharmaceuticals had a recent Job posting/layoffs
Product Launch: Get notified when Rhythm Pharmaceuticals launches new products
Check out if Rhythm Pharmaceuticals is spiking on competitors!
Website visits: Recent activity has been detected on your website
Check if Rhythm Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Rhythm Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Rhythm Pharmaceuticals has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Rhythm Pharmaceuticals recently announced quarterly report
Recommended Actions
Find VP level buyers at Rhythm Pharmaceuticals
Find 2 more new buyers
Compare Similar Companies to Rhythm Pharmaceuticals
Compare insights from companies similar to Rhythm Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Rhythm Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Rhythm Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Rhythm Pharmaceuticals.
Rhythm Pharmaceuticals financials insights
Gather financial insights about Rhythm Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2010
Series A
$40M
2012
Series B
$33M
2017
Other Financing Round
$41M
Stock Offering
$138M
2018
Stock Offering
$174M
2019
Stock Offering
$172.5M
2022
Debt
$100M
2024
Series A
$150M
Rhythm Pharmaceuticals Tech Stack
A closer look at the technologies used by Rhythm Pharmaceuticals
Most Recent Scoops
Open Position
Open Position
Open Position
Person-Based
Earnings, Finance
Open Position
Rhythm Pharmaceuticals News & Media
Rhythm Pharmaceuticals Q2 Earnings Call Highlights
Rhythm Pharmaceuticals (NASDAQ:RYTM) reported second-quarter 2026 global net product sales of $71.3 million for IMCIVREE, up 19% sequentially from $60.1 million in the first quarter, as the company cited an early positive reception to its U.S. launch in acquired hypothalamic obesity, or HO. Chief ERhythm Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update
-- U.S. launch of IMCIVREE® (setmelanotide) for acquired hypothalamic obesity (HO) starts strong with more than 400 patient start forms since FDA approval as of June 30, 2026 -- -- Second quarter 2026 net product revenue from global sales of IMCIVREE of $71.3 million -- -- Weekly injectable MC4R agonist RM-718 achieved mean BMI reduction of 11.6% in patients with acquired HO (n=7) after 16 weeks of treatment -- -- Phase 3 TRANSCEND Trial ResultsRhythm Pharmaceuticals Announces Preliminary Data from Phase 2 Trial that Showed RM-718 Demonstrated Positive Efficacy Signal in Acquired Hypothalamic Obesity
-- -11.6% mean reduction in BMI from baseline at Week 16 (n=7) -- -- BMI reductions consistent with setmelanotide and bivamelagon --Rhythm Pharmaceuticals to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
BOSTON, July 21, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, August 4, 2026 to report its second quarter 2026 financial results and provide a corporate update.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Rhythm Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Rhythm Pharmaceuticals is a biopharmaceutical research and development company focused on developing precision medicines for rare genetic obesity disorders. The company specializes in treatments targeting the melanocortin-4 receptor pathway diseases that cause hyperphagia and severe obesity. Founded in 2008, Rhythm Pharmaceuticals conducts scientif... Read More
